ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!GTBP Company Profile and Key Details
GT Biopharma, Inc.
GTBP Stock Price Chart
Stock Price Today
GT Biopharma, Inc. (GTBP) stock surged +21.18%, trading at $2.46 on NASDAQ, up from the previous close of $2.03. The stock opened at $2.44, fluctuating between $2.02 and $3.12 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Company Information
| Employees | 2 |
| Beta | 0.59 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
GT Biopharma, Inc. (NASDAQ: GTBP) stock price is $2.46 in the last trading session. During the trading session, GTBP stock reached the peak price of $3.12 while $2.02 was the lowest point it dropped to. The percentage change in GTBP stock occurred in the recent session was 21.18% while the dollar amount for the price change in GTBP stock was $0.43.
The NASDAQ listed GTBP is part of Biotechnology industry that operates in the broader Healthcare sector. GT Biopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Jeffrey S. Miller M.D.
Consulting Chief Scientific Officer & Scientific Advisor
Dr. Gregory I. Berk M.D.
Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board
Dr. Gavin S. Choy MBA, PharmD
Chief Clinical Devel. Officer
Mr. Michael Martin Breen
Interim Chief Executive Officer & Executive Chairman
Ms. Stacy Herb M.B.A., M.P.H.
Senior Vice President of Portfolio Management
Mr. Manu Ohri
Chief Financial Officer & Sec.
GTBP's closing price is 18.02% higher than its 52-week low of $1.72 where as its distance from 52-week high of $10.66 is -80.96%.
Number of GTBP employees currently stands at 2.
Official Website of GTBP is: https://www.gtbiopharma.com
GTBP could be contacted at phone 415 919 4040 and can also be accessed through its website. GTBP operates from 8000 Marina Boulevard, Brisbane, CA 94005, United States.
GTBP stock volume for the day was 26.58M shares. The average number of GTBP shares traded daily for last 3 months was 471.54K.
The market value of GTBP currently stands at $5.50M with its latest stock price at $2.46 and 2.23M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com